Published in AIDS Weekly, February 10th, 1997
The approach employs priming immunizations with a recombinant canarypox virus (ALVAC, Virogenetics), dubbed vCP205, followed by boosting immunizations with recombinant HIV gp120 envelope glycoprotein (rgp120MN in MF59 adjuvant, Chiron/Biocine).
Lawrence Corey of the University of Washington, Seattle, and colleagues from the NIAID AIDS Vaccine Evaluation Group (AVEG) reported the latest findings from AVEG study 022 in a late-breaking news session at the Fourth Conference on Retroviruses and Opportunistic Infections, held January 22-26 in Washington,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.